Your browser doesn't support javascript.
loading
Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.
Glorieux, Christophe; Xia, Xiaojun; You, Xin; Wang, Zining; Han, Yi; Yang, Jing; Noppe, Gauthier; Meester, Christophe de; Ling, Jianhua; Robert, Annie; Zhang, Hui; Li, Sheng-Ping; Wang, Huamin; Chiao, Paul J; Zhang, Li; Li, Xiaobing; Huang, Peng.
Afiliação
  • Glorieux C; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Xia X; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • You X; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Wang Z; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Han Y; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Yang J; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Noppe G; Department of Quality Control, MaSTherCell, Gosselies 6041, Belgium.
  • Meester C; Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels 1200, Belgium.
  • Ling J; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.
  • Robert A; Pôle Epidémiologie et Biostatistique, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels 1200, Belgium.
  • Zhang H; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Metabolic Innovation Center, Sun Yat-Sen University, Guangzhou 510060, China.
  • Li SP; Department of Hepatobiliary and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Wang H; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.
  • Chiao PJ; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, TX, USA.
  • Zhang L; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
  • Li X; The First Department of Thoracic Oncology, Hubei Cancer Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, China. Electronic address: lixiaobing0629@126.com.
  • Huang P; Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China; Metabolic Innovation Center, Sun Yat-Sen University, Guangzhou 510060, China. Electronic address: huangpeng@sysucc.org.cn.
J Adv Res ; 40: 109-124, 2022 09.
Article em En | MEDLINE | ID: mdl-36100320
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Neoplasias Pulmonares / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: J Adv Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Neoplasias Pulmonares / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: J Adv Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China